Drug Profile
Fibrinogen-coated albumin microcapsules
Alternative Names: FAMs; Fibrinogen microcapsules; SynthocytesLatest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator Quadrant Healthcare
- Developer ProFibrix; Quadrant Healthcare
- Class Acute-phase proteins; Albumins; Antihaemorrhagics; Blood coagulation factors; Coagulants; Protein precursors
- Mechanism of Action Fibrinogen replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Thrombocytopenia
Most Recent Events
- 06 Jan 2020 The Medicines Company has been acquired by Novartis
- 16 Jul 2016 No recent reports of development identified for preclinical development in Thrombocytopenia in Denmark (IV, Injection)
- 05 Aug 2013 ProFibrix has been acquired by The Medicines Company